News/Events

There are many variables to consider when producing novel recombinant proteins, and for those with no prior precedent for recombinant protein production, it may be beneficial to generate multiple variants of a protein construct.

You don’t need a four-leaf clover to have good luck with your recombinant protein production. Make your own luck. Contact Proteos today for protein expression and purification services that are customized to fit your needs.

Proteos has secured a discounted registration fee for you to attend the PEGS Summit in Boston, MA. Register today and take $150 off the current rate.

Proteos is an industry leader in the production of high-quality recombinant proteins from multiple expression platforms. One of the first variables to consider when producing recombinant proteins is the optimal expression system.

There are many variables to consider when producing novel recombinant proteins. These variables include selection of an expression system, construct design, and scale.

There are many variables to consider when producing recombinant proteins, and more specifically recombinant antigens. These variables include construct design, affinity tags, expression system, purification scheme, formulation, and characterization. Here we will focus on methods for determining protein quality.

There are many variables to consider when producing recombinant proteins, and more specifically recombinant antigens. These variables include construct design, affinity tags, expression system, purification scheme, formulation, and characterization. Here we will focus on considerations for long-term storage of recombinant antigens.

There are many variables to consider when producing recombinant proteins, and more specifically recombinant antigens. These variables include construct design, affinity tags, expression system, purification scheme, formulation, and characterization. Here we will focus on selecting an appropriate expression system for recombinant antigen production.

There are many variables to consider when producing recombinant proteins, and more specifically recombinant antigens. These variables include expression system, purification techniques, protein tags, formulation, and assessment.

Proteos is an industry leader in the production of high-quality recombinant antibodies for drug discovery research. Here we will focus on the benefits of producing mAbs recombinantly in mammalian cells.

Proteos is an industry leader in the production of high-quality recombinant antibodies for drug discovery research. There are multiple methods for production of monoclonal antibodies, including hybridoma cell lines and recombinant protein technology. The following information will discuss some of the limitations of hybridoma production.

More than 6 million people worldwide are living with Parkinson’s Disease.  Proteos has proudly partnered with The Michael J. Fox Foundation to provide high-quality protein reagents in support of Parkinson’s disease research.